Ensign Peak Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Ensign Peak Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-177,457	Closed	-$19M	–	1791
2023 Q1	$19M	Buy	177,457 +8,250	+5%	+$950K	0.04%	289
2022 Q4	$18.6M	Buy	169,207 +101,750	+151%	+$6.6M	0.04%	306
2022 Q3	$3.98M	Buy	67,457 +65,897	+4,224%	+$3.02M	0.01%	582
2022 Q2	$44K	Hold	1,560	–	–	﹤0.01%	2078
2022 Q1	$59K	Buy	+1,560	New	+$61.7K	﹤0.01%	2108

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Ensign Peak Advisors's RXDX Position: Q2 2023 in Review

Ensign Peak Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 177,457 shares — an estimated $19M sold.

Ensign Peak Advisors first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $19M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Ensign Peak Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ensign Peak Advisors sold 177,457 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $19M.
Ensign Peak Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Ensign Peak Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $19M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Ensign Peak Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.